USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 2, 2005, and the six months ended on that date. USANA Health Sciences, Inc. develops, manufactures, and distributes nutritional and personal care products through a network marketing system (Direct Selling) and a Contract Manufacturing segment. As of July 2, 2005, the company reported 125,000 active Associates and 66,000 active Preferred Customers worldwide.
Key Financial Metrics
| Metric | Q2 2005 | Q2 2004 | 6 Months 2005 | 6 Months 2004 |
|---|---|---|---|---|
| Net Sales | $82.0 million | $67.2 million | $158.6 million | $129.0 million |
| Gross Profit | $62.5 million (76.2%) | $51.1 million (75.9%) | $121.1 million (76.3%) | $97.8 million (75.8%) |
| Net Earnings | $9.5 million | $7.4 million | $18.5 million | $13.6 million |
| Diluted EPS | $0.48 | $0.36 | $0.93 | $0.66 |
| Cash & Equivalents | $20.4 million | $13.8 million (end of Q2 '04) | $20.4 million | $13.8 million |
| Operating Cash Flow | N/A | N/A | $22.0 million | $16.9 million |
| Debt | $0 | $0 | $0 | $0 |
Note: All figures in millions unless otherwise noted. Percentages represent gross margin.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22.0% in Q2 2005 and 22.9% for the six-month period compared to the prior year. This was driven by a 20.2% increase in active Associates and favorable foreign currency translation ($3.1 million impact in Q2).
- Profitability: Net earnings rose 28.7% in Q2 and 35.6% for the six months. Diluted EPS increased 33.3% in Q2.
- Segment Performance: The Direct Selling segment grew significantly, while the Contract Manufacturing segment saw a decline in sales due to a strategic focus on the internal Sensé product line.
- Share Repurchases: The company spent $15.0 million to repurchase 353,000 shares during the first six months of 2005.
- Inventory: Inventories increased from $17.7 million to $22.0 million, reflecting higher raw material costs and production buildup.
Guidance, Outlook, and Risks
- Guidance: Management expects Q3 2005 net sales between $82 million and $84 million. Full-year 2005 sales are projected between $325 million and $330 million. Diluted EPS is expected to be $0.47–$0.49 for Q3 and $1.88–$1.92 for the full year.
- Margin Outlook: Gross profit margins are expected to improve modestly in Q3. However, Associate incentives are projected to rise to approximately 41% of net sales due to new promotional initiatives.
- Key Risks:
- Raw Materials: Persistent shortages and higher costs for ingredients like Coenzyme Q10.
- Regulatory: Scrutiny of network marketing practices and government regulation of nutritional supplements.
- Market Expansion: Risks associated with delays in new market openings (planned for Q4 2005) and foreign currency fluctuations.
- Associate Turnover: Dependence on the network marketing model and high turnover rates among Associates.
Investor Verification Checklist
- Associate Growth Quality: Verify the sustainability of the 20.2% increase in active Associates and the impact of new incentives on future margins.
- Raw Material Costs: Monitor the resolution of Coenzyme Q10 shortages and their effect on gross margins.
- Share Repurchase Impact: Assess the remaining capacity under the $40 million share repurchase plan and its effect on liquidity.
- Contract Manufacturing: Evaluate the long-term viability of the Contract Manufacturing segment given its recent sales decline and low margins.
- Foreign Currency Exposure: Review the impact of the strengthening U.S. dollar on future international sales translation.